Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKZ | Q13574 | 18/20 | 0.36 |
| ▸ | DGKA | P23743 | 11/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499640 | 0.90 | NQO1 (0.34) | DGKZDGKANQO1SYK | |
| SCHEMBL28556963 | 0.78 | NQO1 (0.41) | DGKZDGKANQO1 | |
| SCHEMBL29499630 | 0.76 | MEN1 (0.41) | — | |
| SCHEMBL29911623 | 0.76 | LMNA (0.33) | — | |
| SCHEMBL29714935 | 0.75 | CDC7 (0.44) | — | |
| SCHEMBL30421173 | 0.74 | NQO1 (0.39) | DGKZDGKANQO1 | |
| SCHEMBL23529927 | 0.73 | NQO1 (0.40) | NQO1 | |
| SCHEMBL30791989 | 0.73 | NQO1 (0.40) | NQO1 | |
| SCHEMBL29911576 | 0.73 | CYP1A2 (0.39) | — | |
| SCHEMBL29499787 | 0.72 | MGAM (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | claimed |
| CN-115175907-B | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2024-08-02 | — | — | CN | claimed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | claimed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | claimed |
| CN-115175907-A | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2022-10-11 | — | — | CN | claimed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | claimed |
| EP-4583876-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | Juno Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152717-A | Combination of T cell therapy and continuous or intermittent DGK inhibitor administration | 朱诺治疗学股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119677740-A | Tertiary amine substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-115175907-B | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117693508-A | Combination of T cell therapy and DGK inhibitors | 朱诺治疗学股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4301755-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Juno Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| CN-115243721-A | Combination of DGK inhibitors and checkpoint antagonists | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115175907-A | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022187406-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | DGKZ 1/4885DGKA 2/4885NQO1 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.